Top Stories
The Danish pharma attributed the upgrade in part to migraine drug Vyepti's continued "strong performance" in the US.
Funnel Biosciences launched in February with support from investor Yijing Capital.
Oyster Therapeutics, previously known as Kesmalea Therapeutics, is looking to develop targeted protein degraders with an initial focus on tau-driven disorders, including Alzheimer's.
The once-daily oral factor XIa inhibitor, now known as Sunharbo, is indicated for patients after a non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack.
The investigation comes on the heels of Novartis confirming last week that it received nine reports of tumours in patients previously treated with the gene therapy since its approval back in 2019.
Conference News
CAPLYTA improved manic symptoms versus placebo as early as Day 3, with improvement sustained through Week 3 and a safety and tolerability profile consistent with prior studiesTwo positive Phase 3 stud...
Real-world results from 3,181 members across 10 employers, to be presented at Obesity Week® 2026, beat every published cohort on the same drug with standard care. The difference: precision biology and...
Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers Phase III PrevenTRON study design specifics for trontinemab ...
FirstWord will be speaking with a leading expert about initial Phase I data for J&J's pasritamig plus JNJ-9401, and how the combo of bispecific antibodies could impact practice patterns in advanced prostate cancer.
New commercial question marks at Ionis Pharmaceuticals seem to be spreading, weighing down sentiment across a swath of newly troubled RNA therapy companies.
